. Author manuscript; available in PMC: 2020 Jan 1.

Published in final edited form as: Eur J Cancer. 2018 Dec 14;107:100–114. doi: 10.1016/j.ejca.2018.11.019

Table A. 5.

Models consisting SNPs and tumor location in the control cohort

		Tumor response			Progression-free survival					Overall Survival

	N	CR+PR	SD+PD	P value^*	Median, months (95%CI)	HR (95%CI)^†	P value^*	HR (95%CI) ^† ^‡	P value^*	Median, months (95%CI)	HR (95%CI)^†	P value^*	HR (95%CI) ^† ^‡	P value^*

Model 1
CCL5 by tumor location				0.97			0.22		0.90			0.067		0.65
Group I	142	85(64%)	47(36%)		11.1(9.9,12.8)	1(Reference)		1(Reference)		27.4(22.3,33.2)	1(Reference)		1(Reference)
Group II	36	21(66%)	11(34%)		9.8(8.6,12.2)	1.10(0.73,1.65)		0.98(0.65,1.50)		28.1(19.5,31.9)	1.16(0.74,1.83)		0.97(0.60,1.55)
Group III	45	25(63%)	15(38%)		8.8(6.6,12.5)	1.38(0.95,2.01)		1.13(0.77,1.67)		23.0(15.9,23.8)	1.58(1.04,2.39)		1.22(0.77,1.92)
Group IV	17	9(60%)	6(40%)		9.3(5.2,12.3)	1.49(0.85,2.60)		0.93(0.51,1.70)		20.6(14.1,23.1)	1.77(0.96,3.27)		0.78(0.37,1.66)

Model 2
CCR5 by tumor location				0.76			0.20		0.46			0.075		0.30
Group I	53	31(69%)	14(31%)		10.7(9.3,13.6)	1(Reference)		1(Reference)		29.6(19.5,36.0)	1(Reference)		1(Reference)
Group II	122	71(61%)	45(39%)		10.8(9.7,11.9)	1.08(0.75,1.54)		1.22(0.84,1.76)		27.4(21.9,30.3)	1.08(0.72,1.63)		1.25(0.82,1.91)
Group III	19	11(69%)	5(31%)		8.8(6.5,12.5)	1.57(0.89,2.76)		1.58(0.89,2.82)		22.7(13.7,29.1)	1.72(0.90,3.28)		1.87(0.95,3.68)
Group IV	41	22(59%)	15(41%)		9.3(6.6,12.3)	1.43(0.90,2.26)		1.13(0.70,1.84)		21.0(14.7,23.8)	1.67(1.01,2.76)		1.12(0.64,1.97)

Novel classification				0.73			0.16		0.47			0.025		0.20
Group I	152	90(65%)	48(35%)		10.8(9.9,12.7)	1(Reference)		1(Reference)		27.5(24.7,32.4)	1(Reference)		1(Reference)
Group II	43	23(61%)	15(39%)		9.7(8.3,11.5)	1.27(0.88,1.84)		1.26(0.87,1.84)		23.2(15.9,28.4)	1.48(0.97,2.25)		1.48(0.95,2.30)
Group III	41	22(59%)	15(41%)		9.3(6.6,12.3)	1.38(0.93,2.04)		1.02(0.67,1.56)		21.0(14.7,23.8)	1.64(1.08,2.50)		1.02(0.62,1.68)

RAS wild-type subgroup

Model 1
CCL5 by tumor location				0.26			0.42		0.85			0.14		0.30
Group I	116	71(66%)	36(34%)		10.8(9.8,12.7)	1(Reference)		1(Reference)		27.5(23.7,33.2)	1(Reference)		1(Reference)
Group II	31	19(68%)	9(32%)		9.7(8.3,11.5)	1.11(0.72,1.71)		0.98(0.62,1.55)		28.0(18.4,31.9)	1.19(0.73,1.93)		1.01(0.61,1.66)
Group III	35	19(61%)	12(39%)		8.8(6.2,12.5)	1.40(0.92,2.15)		1.12(0.72,1.73)		23.0(14.2,23.8)	1.70(1.06,2.72)		1.28(0.76,2.14)
Group IV	10	3(33%)	6(67%)		9.0(1.6,15.9)	1.29(0.63,2.67)		0.78(0.35,1.72)		20.6(7.1,58.7)	1.35(0.62,2.97)		0.53(0.20,1.37)

Model 2
CCR5 by tumor location				0.52			0.37		0.66			0.15		0.77
Group I	46	25(64%)	14(36%)		10.1(8.5,12.8)	1(Reference)		1(Reference)		26.1(19.5,32.4)	1(Reference)		1(Reference)
Group II	99	62(66%)	32(34%)		11.1(9.7,12.0)	1.02(0.69,1.49)		1.19(0.80,1.78)		28.1(24.7,33.2)	0.88(0.57,1.35)		1.12(0.71,1.77)
Group III	14	8(67%)	4(33%)		9.0(6.5,15.7)	1.33(0.69,2.55)		1.48(0.77,2.87)		23.2(14.2,29.1)	1.29(0.61,2.72)		1.50(0.70,3.25)
Group IV	29	13(50%)	13(50%)		7.8(5.7,12.3)	1.45(0.86,2.45)		1.07(0.61,1.87)		21.0(13.0,24.2)	1.51(0.86,2.64)		1.06(0.55,2.02)

Novel classification				0.21			0.21		0.58			0.069		0.49
Group I	124	77(68%)	37(32%)		10.7(9.7,12.7)	1(Reference)		1(Reference)		28.8(24.8,32.4)	1(Reference)		1(Reference)
Group II	34	18(60%)	12(40%)		9.7(8.3,11.8)	1.21(0.80,1.83)		1.24(0.82,1.89)		23.6(14.8,28.6)	1.31(0.82,2.11)		1.35(0.82,2.22)
Group III	29	13(50%)	13(50%)		7.8(5.7,12.3)	1.46(0.92,2.30)		0.99(0.60,1.64)		21.0(13.0,24.2)	1.70(1.05,2.77)		1.03(0.57,1.87)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. P values<0.05 were shown in bold.

P value was based on the Fisher’s exact test for response, log-rank test in the univariate analysis

^(†)

and Wald test in the multivariable analysis within Cox regression model

^(‡)

adjusted for sex, ECOG performance status, liver metastasis, resection of the primary tumors, RAS and BRAF status.